Asset Details
Do you wish to reserve the book?
Upadacitinib: First Approval
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Upadacitinib: First Approval
Do you wish to request the book?
Upadacitinib: First Approval
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Upadacitinib: First Approval
2019
Overview
Upadacitinib (Rinvoq™), an orally-administered Janus kinase 1 (JAK-1) inhibitor, is being developed by AbbVie for the treatment of rheumatoid arthritis. In August 2019, based on positive results from multinational phase III trials conducted in patients with rheumatoid arthritis, upadacitinib received marketing approval in the USA for the treatment of moderately to severely active rheumatoid arthritis and an inadequate response or intolerance to methotrexate. This article summarizes the milestones in the development of upadacitinib leading to this first approval for the treatment of rheumatoid arthritis.
Publisher
Springer International Publishing,Springer Nature B.V
Subject
/ Antirheumatic Agents - chemistry
/ Antirheumatic Agents - pharmacology
/ Arthritis, Rheumatoid - drug therapy
/ Arthritis, Rheumatoid - metabolism
/ Heterocyclic Compounds, 3-Ring - chemistry
/ Heterocyclic Compounds, 3-Ring - pharmacology
/ Humans
/ Janus Kinase 1 - antagonists & inhibitors
/ Kinases
/ Medicine
/ Methotrexate - adverse effects
/ Plasma
/ Protein Kinase Inhibitors - chemistry
